Takeda Pharmaceutical Co Ltd (TKPHF) Cash from Investing Activities (2018 - 2026)

Takeda Pharmaceutical's Cash from Investing Activities history runs 9 years deep, the most recent figure standing at -$550.2 million for Q2 2026.

• In Q2 2026, Cash from Investing Activities fell 139.86% year-over-year to -$550.2 million; the TTM figure through Jun 2026 stood at -$2.7 billion (down 68.91% YoY), while the FY2026 annual figure was -$2.5 billion, down 1.77% from the prior year.
• Cash from Investing Activities for Q2 2026 stood at -$550.2 million, down from -$369.9 million in the prior quarter.
• The five-year high for Cash from Investing Activities was -$129.0 million in Q1 2025, with the low at -$3.3 billion in Q1 2023.
• The 5-year median for Cash from Investing Activities is -$461.6 million (2024), against an average of -$747.4 million.
• The sharpest annual moves came in 2023 and 2024: Cash from Investing Activities slumped 1402.64% in 2023, then surged 87.48% in 2024.
• Takeda Pharmaceutical's Cash from Investing Activities stood at -$330.5 million in 2022, then plunged by 54.08% to -$509.2 million in 2023, then slumped by 49.27% to -$760.1 million in 2024, then plunged by 96.45% to -$1.5 billion in 2025, then soared by 63.15% to -$550.2 million in 2026.
• Business Quant data shows TKPHF's Cash from Investing Activities at -$550.2 million in Q2 2026, -$369.9 million in Q1 2026, and -$1.5 billion in Q4 2025.